**Table S4:** **Apramycin studies published *vs.* the present study**

|  |  |  |  |
| --- | --- | --- | --- |
| **APR activity evaluated against various pathogens- published reports vs. present study (Kaur et.al.)** | | | |
| **Pathogens/ Materials** | **Studies** | **Assays/ Models** | **Reference** |
| Cell lines | Cytotoxicity | Cell lines / models | Bonaventura (34) |
| *Gram-negative pathogens:  Escherichia coli* (combination MIC), *Klebsiella pneumoniae* (hyper-virulent clinical strain), *Pseudomonas*, *Acinetobacter baumannii*. | In-vitro studies | MIC, Biofilm & Clinical isolates (sensitive or aminoglycoside/ carbapenem-resistant) | Kim (35), Atlas (36), Hao (37), Gysin (31) |
| Target/ MoA studies | In-vitro studies | Target/ MoA & Hu ribosomal decoding site | Hermann (38), Bordeleau (39) |
| *Mycobacterium abscessus* | In-vitro studies | Killing kinetics | Selchow (32) |
| In-vivo studies | Animal efficacy |  |
| *Mycobacterium tuberculosis* | In-vivo efficacy in murine models of TB | | This study (Kaur et.al.) |
| In-vivo models of replicating Mtb | **Acute model:** - monotherapy  - against replicating Mtb | Meyer (20) |
| In-vivo models of non-replicating Mtb | **Chronic model:** - combination with HREZ regimen - against non-replicating Mtb | This study (Kaur et.al.) |
| In-vitro studies | | This study (Kaur et.al.) |
| In-vitro models of replicating & non-replicating Mtb | **In replicating models:**  - MIC and MBC - MIC90 in MDR clinical isolates - Killing kinetic - Cytotoxicity  **In non-replicating models:** - Intracellular efficacy - Biofilm | This study (Kaur et.al.) |